Analysts Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Target Price at $11.00

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $11.00.

EPRX has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. Cantor Fitzgerald assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, July 24th. They set an “overweight” rating and a $11.00 price objective on the stock. Finally, Canaccord Genuity Group assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, June 16th. They issued a “speculative buy” rating on the stock.

Institutional Trading of Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC purchased a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at about $31,000. Scotia Capital Inc. lifted its holdings in shares of Eupraxia Pharmaceuticals by 11.6% in the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company’s stock valued at $5,072,000 after purchasing an additional 160,960 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after purchasing an additional 59,683 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares in the last quarter.

Eupraxia Pharmaceuticals Stock Down 0.3%

Shares of Eupraxia Pharmaceuticals stock opened at $6.05 on Tuesday. The firm has a market cap of $217.56 million, a price-to-earnings ratio of -7.12 and a beta of 1.51. Eupraxia Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $7.19. The company’s 50-day simple moving average is $5.56 and its 200-day simple moving average is $4.70.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). Equities research analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.